AAP Implantate Adjusts FY 2023 Revenue & EBITDA Forecast; Takes Staff Action for Balanced Cash Flow

• aap Implantate AG adjusts the forecast for sales and EBITDA for the financial year 2023
• Sales for 2023 are expected to be between EUR 11.2 million and EUR 11.8 million, lower than the previous forecast
• EBITDA for 2023 is expected to be between EUR -3.0 million and EUR -2.5 million, also lower than the previous forecast
• The company plans to implement extensive staff reductions and cost reductions
• The workforce will be reduced by around 13% by the end of the current financial year
• The aim of the measures is to save more than EUR 1 million in personnel costs annually from 2024 and achieve a positive EBITDA and balanced cash flow in the operating trauma business.

The price of aap Implantate at the time of the news was 0,7425EUR and was down -7,19 % compared with the previous day.

aap Implantate

-3,49 %

-4,46 %

+39,30 %

+74,24 %

+21,80 %

-55,54 %

-85,72 %

ISIN:DE000A3H2101WKN:A3H210

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• Max